When I came into residency, I wanted to work in oncology and global medicine, which focuses on ensuring that the standard of care for any disease is available in an equitable way across the world.

I met Salvia Jain, lead investigator of PETAL Consortium, during my intern year in the lymphoma service. At that time, I had never heard of T-cell lymphomas, but during my service, I realized that there's a high clinical and scientific need for research in that area. Since Salvia had the passion to research the disease on a global scale, PETAL really aligned with my interests.

My research focus was on sequencing DNA and RNA and how we can use that to further understand the subtypes of T-cell lymphomas. Through sequencing, we correlate which molecular signatures (patterns in DNA or RNA) respond better or worse to certain treatments.

Using machine learning and other statistical methods, we identify molecular signatures that help us understand why a certain tumor behaves in a certain way or why a certain patient is responding to a certain treatment. We take that information to guide future treatment plans.